Records containing: Peripheral T-cell Lymphoma
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-04-13A Phase 1/2, Open-Label, Nonrandomized, Multi-arm Umbrella Study of Biomarker-Selected Dual-Target CAR-T Cell Modules in Adults With Relapsed or Refractory Hematologic Malignancies
-
CLINICAL_TRIALS study record update · 2026-04-13Constitutive IL7R (C7R) Modified Banked Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes (CD30.CAR-EBVSTs) in Patients With Relapsed or Refractory CD30-Positive Lymphomas
-
CLINICAL_TRIALS study record update · 2026-04-02A Phase II Study of Anti-Programmed Death-1(PD-1) Antibody Sintilimab Plus Histone Deacetylase(HDAC) Inhibitor Chidamide in Patients With Relapsed/ Refractory Peripheral T-cell Lymphoma
-
CLINICAL_TRIALS study record update · 2026-03-02Karyopharm Expanded Access Program for Selinexor
-
CLINICAL_TRIALS study record update · 2026-01-05A Phase 1/2, Open-label, Multi-center Study to Evaluate theSafety and Efficacy of Selinexor Combined With Chemotherapy orTislelizumab in Relapsed or Refractory Mature T and NK Cell Lymphoma
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2025-12-16A Phase II Trial of JAK Inhibitor Added to Immunotherapy for Treatment of Relapsed/Refractory T-cell Lymphoma and 9p Amplified Lymphomas
-
CLINICAL_TRIALS study record update · 2025-12-05PI3Kδ Inhibitor Linperlisib Combined With HDAC Inhibitor Chidamide Versus CHOP in Patients With Peripheral T-cell Lymphoma: a Multicenter, Open Label, Phase Ib/II Study
-
CLINICAL_TRIALS study record update · 2025-12-02Optimization of the First-line Therapy of T-cell Lymphomas
-
CLINICAL_TRIALS study record update · 2025-11-18A Phase 3, Open-Label, Randomized, Multinational Study to Investigate the Anti-tumor Efficacy of Golidocitinib Versus Investigator's Choice in Adult Patients With Relapsed/Refractory Peripheral T-cell Lymphoma
-
CLINICAL_TRIALS study record update · 2025-09-22A Phase 1a/1b Trial in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma to Determine the Safety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, a Fenretinide Phospholipid Suspension (12.5 mg/mL) for Intravenous Infusion
-
CLINICAL_TRIALS study record update · 2025-07-18A Prospective, Exploratory Clinical Study of Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory Peripheral T-cell Lymphoma Patients
-
CLINICAL_TRIALS study record update · 2025-07-08A Phase 1, First-In-Human, Open-Label, Dose-Escalating Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Ascending Intravenous Doses of BITR2101 (Anti-TNFR2) in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Including Cutaneous and Peripheral T Cell Lymphoma
-
CLINICAL_TRIALS study record update · 2025-07-04A Phase II, Open-Label, Multicenter Study to Assess the Safety and Anti-Tumor Efficacy of AZD4205 in Participants With Peripheral T Cell Lymphoma Who Have Responded After First-Line Standard Therapy
-
CLINICAL_TRIALS study record update · 2025-06-04Observational Study in Japanese Patients With Peripheral T-Cell Lymphoma Who Received Second-Line Therapy
-
CLINICAL_TRIALS study record update · 2025-05-15A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression
-
CLINICAL_TRIALS study record update · 2025-04-06A Phase 1, Open-Label, Single-Arm Study of the Safety, Pharmacokinetics and Efficacy of CHT101 in Subjects With Relapsed or Refractory T or B Cell Hematological Malignancies
-
CLINICAL_TRIALS study record update · 2025-02-28A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
-
CLINICAL_TRIALS study record update · 2025-02-10A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies
-
CLINICAL_TRIALS study record update · 2025-01-03A Phase I/II, Open-Label, Single-Arm Study of Chidamide in Combination With Golidocitinib in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
-
CLINICAL_TRIALS study record update · 2024-12-18A Phase I/II Study of Golidocitinib in Combination with CHOP in Patients with Newly Diagnosed Peripheral T Cell Lymphoma
-
CLINICAL_TRIALS study record update · 2024-05-17Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma：a Single-Arm, Open Lable， Multicenter Clinical Trial（LINCH Study）
-
CLINICAL_TRIALS study record update · 2024-05-14A Phase Ib/II, Open-label, Multi-center Study of SHR2554 With CHOP/CHOEP in Treatment-naïve Patients With Peripheral T-cell Lymphoma
-
CLINICAL_TRIALS study record update · 2024-04-22Next-Generation Sequencing-based, Tumor- and Plasma-informed Droplet Digital PCR Assay for Detection of Circulating Tumor DNA in Peripheral T-cell Lymphomas
-
CLINICAL_TRIALS study record update · 2024-04-10Phase II Study of Romidepsin Plus Lenalidomide for Patients With Previously Untreated PTCL
-
CLINICAL_TRIALS study record update · 2024-04-02A Phase I Trial to Evaluate Safety and Immunogenicity of a Cytomegalovirus Peptide Vaccine Co-Injected With PF-03512676 Adjuvant in Recipients of Allogeneic Hematopoietic Stem Cell Transplant